We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-4.24%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$733M
AUM Growth
+$21.5M
Cap. Flow
+$93.1M
Cap. Flow %
12.7%
Top 10 Hldgs %
32.84%
Holding
138
New
34
Increased
32
Reduced
32
Closed
20

Top Buys

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$25.7M
2
SKYE icon
Skye Bioscience
SKYE
+$15.4M
3
ASML icon
ASML
ASML
+$9.52M
4
CRM icon
Salesforce
CRM
+$8.99M
5
BBIO icon
BridgeBio Pharma
BBIO
+$8.86M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$16.9M
2
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$9.57M
3
CAMT icon
Camtek
CAMT
+$6.97M
4
CATX icon
Perspective Therapeutics
CATX
+$6.61M
5
NVMI
Nova
NVMI
+$6.23M

Sector Composition

Rank Sector Weight
1 Healthcare 59.43%
2 Technology 17.13%
3 Communication Services 3.05%
4 Consumer Discretionary 3%
5 Utilities 0.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEN icon
101
Compugen
CGEN
$222M
$1.24M 0.17%
739,239
-30,000
-4% -$62.5K
KZR
102
DELISTED
Kezar Life Sciences
KZR
$1.23M 0.17%
205,168
– –
INSM icon
103
Insmed
INSM
$21.4B
$1.11M 0.15%
+16,589
New +$643K
APRE icon
104
Aprea Therapeutics
APRE
$7.68M
$1.1M 0.15%
270,000
– –
TSM icon
105
TSMC
TSM
$2.1T
$982K 0.13%
+5,650
New +$857K
ELEV
106
DELISTED
Elevation Oncology
ELEV
$891K 0.12%
330,000
-100,000
-23% -$377K
VRNS icon
107
Varonis Systems
VRNS
$4.59B
$768K 0.1%
16,000
-4,000
-20% -$177K
RNAC icon
108
Cartesian Therapeutics
RNAC
$229M
$677K 0.09%
25,070
+24,234
+2,899% +$578K
ARGX icon
109
argenx
ARGX
$53.4B
$669K 0.09%
+1,556
New +$596K
LVTX
110
DELISTED
LAVA Therapeutics
LVTX
$662K 0.09%
367,582
– –
PRME icon
111
Prime Medicine
PRME
$527M
$655K 0.09%
127,424
-77,818
-38% -$472K
ICL icon
112
ICL Group
ICL
$6.53B
$459K 0.06%
107,238
-23,237
-18% -$109K
FULC icon
113
PUT
Fulcrum Therapeutics
FULC
$273M
$366K 0.05%
+59,000
New +$447K
IMTXW
114
DELISTED
Immatics N.V. Warrants
IMTXW
$277K 0.04%
100,000
– –
CAMT icon
115
Camtek
CAMT
$6.18B
$243K 0.03%
1,940
-72,969
-97% -$6.97M
GOSS icon
116
Gossamer Bio
GOSS
$82.9M
$200K 0.03%
222,134
-805,000
-78% -$602K
ARBE icon
117
Arbe Robotics
ARBE
$80.3M
$82.4K 0.01%
43,165
– –
AMLX icon
118
Amylyx Pharmaceuticals
AMLX
$2.26B
$68.5K 0.01%
36,050
-231,200
-87% -$448K
ACAD icon
119
CALL
Acadia Pharmaceuticals
ACAD
$4.43B
– –
-100,000
Closed -$1.85M
ALNY icon
120
CALL
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-20,000
Closed -$2.99M
AMD icon
121
Advanced Micro Devices
AMD
$776B
– –
-11,000
Closed -$1.99M
AMLX icon
122
CALL
Amylyx Pharmaceuticals
AMLX
$2.26B
– –
-240,000
Closed -$682K
ANNX icon
123
PUT
Annexon
ANNX
$834M
– –
-11,400
Closed -$81.7K
CRBP icon
124
Corbus Pharmaceuticals
CRBP
$166M
– –
-35,000
Closed -$1.37M
ESTC icon
125
Elastic
ESTC
$6.84B
– –
-20,000
Closed -$2M
2 3 4
5
6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2024 Portfolio in Review

As of Q2 2024, Sphera Funds Management held 138 positions worth $733M, up 3% from $712M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Sphera Funds Management deployed $93.1M of net new capital in Q2 2024, opening 34 new positions and adding to 32 existing holdings. Its largest new stake was Skye Bioscience: 1,298,312 shares worth $10.4M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 65% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $16.9M trimmed.

  • Sphera Funds Management's largest Q2 2024 buy was Skye Bioscience: 1,298,312 shares worth $10.4M.
  • Sphera Funds Management added most to Broadcom in Q2 2024, an estimated $25.7M increase.
  • Sphera Funds Management's biggest Q2 2024 reduction was Teva Pharmaceuticals, cutting an estimated $16.9M.
  • Sphera Funds Management fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $9.57M.
  • Sphera Funds Management's ten largest holdings make up 33% of its $733M portfolio in Q2 2024.
  • Sphera Funds Management opened 34 new positions and closed 20 in Q2 2024.
  • Sphera Funds Management's portfolio value rose 3% quarter-over-quarter to $733M.

Based on Sphera Funds Management's 13F filing for Q2 2024, filed 14 Aug 2024.